No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical benefit...
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained...
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished...
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim...
--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from...
HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients...
HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley...
Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract Profound mast cell depletion did not result in improved clinical outcomes...